Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 10/20 | 0.95 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920707 | 0.98 | ACHE (1.00) | ACHETSHROPRM1BLMSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28469713 | 0.95 | ACHE (0.95) | ACHETSHROPRM1BLMSMN1; SMN2 | |
| Water SCHEMBL11727004 | 0.95 | ACHE (0.95) | ACHETSHROPRM1BLMSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30945416 | 0.95 | ACHE (0.95) | ACHETSHROPRM1BLMSMN1; SMN2 | |
| Dimethylcarbate SCHEMBL4413046 | 0.81 | ACHE (0.69) | ACHETSHROPRM1BLMSMN1; SMN2 | |
| Dimethylcarbate SCHEMBL4413044 | 0.80 | ACHE (0.67) | ACHETSHROPRM1BLMSMN1; SMN2 | |
| SCHEMBL26628889 | 0.79 | ACHE (0.67) | ACHETSHROPRM1BLMSMN1; SMN2 | |
| Iodide SCHEMBL9151128 | 0.76 | ACHE (0.66) | ACHETSHROPRM1BLMSMN1; SMN2 | |
| Edrophonium SCHEMBL8009388 | 0.76 | ACHE (1.00) | ACHETSHROPRM1BLMSMN1; SMN2 | |
| Edrophonium SCHEMBL34790 | 0.76 | ACHE (1.00) | ACHETSHROPRM1BLMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221968-A1 | TREATMENTS AND METHODS FOR INCREASING DOPAMINE | UNIV OXFORD INNOVATION LTD (GB) | 2025-07-10 | — | — | US | claimed |
| EP-4493171-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | Zhang, Yanfeng C/o Oxford University Innovation Limited (GB) | 2025-01-22 | — | — | EP | claimed |
| CN-118731967-A | Contact line detection and pillar identification algorithm based on two-dimensional laser radar | 绵阳师范学院 | 2024-10-01 | — | — | CN | claimed |
| WO-2023175357-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-09-21 | — | — | WO | claimed |
| US-20220309248-A1 | METHOD AND SYSTEM FOR PRODUCT KNOWLEDGE FUSION | China Academy of Art (CN) | 2022-09-29 | — | — | US | claimed |
| CN-112939873-B | Trimethoprim hapten TMPH, artificial antigen, antibody and preparation method and application thereof | 华南农业大学 | 2022-03-25 | — | — | CN | claimed |
| US-20260101051-A1 | SYSTEM AND METHOD FOR INTRA PREDICTION USING FRACTIONAL-PEL BLOCK VECTOR | GUANGDONG OPPO MOBILE TELECOMMUNICATIONS CORP LTD (CN) | 2026-04-09 | — | — | US | disclosed |
| EP-3568400-B1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-D]PYRIMIDINE-2,7-DIONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025217647-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4270194-B1 | MONITORING DEVICE AND MONITORING METHOD | INTER UNIV RESEARCH INSTITUTE CORPORATION RESEARCH ORGANIZATION OF INFORMATION AND SYSTEMS (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-20250221968-A1 | TREATMENTS AND METHODS FOR INCREASING DOPAMINE | UNIV OXFORD INNOVATION LTD (GB) | 2025-07-10 | — | — | US | disclosed |
| CN-120004867-A | Nitrogen-containing benzoxazole seven-membered ring compound and preparation method thereof | 扬州大学 | 2025-05-16 | — | — | CN | disclosed |
| EP-4551561-A1 | METHOD FOR PRODUCING 2,4,6-SUBSTITUTED TRIAZINES | Symrise AG (DE) | 2025-05-14 | — | — | EP | disclosed |
| CN-114585370-A | Oligonucleotide compositions and methods of use thereof | 波涛生命科学有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-109843634-B | Vehicle control device | 株式会社电装 | 2022-05-31 | — | — | CN | disclosed |
| CN-114502177-A | Oligonucleotide compositions and methods of use thereof | 波涛生命科学有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-109689051-B | Use of inhibitors of mitochondrial activity for the treatment of acute myeloid leukemia with poor prognosis | 蒙特利尔大学 | 2022-03-29 | — | — | CN | disclosed |
| CN-112939873-B | Trimethoprim hapten TMPH, artificial antigen, antibody and preparation method and application thereof | 华南农业大学 | 2022-03-25 | — | — | CN | disclosed |
| CN-112939873-B | Trimethoprim hapten TMPH, artificial antigen, antibody and preparation method and application thereof | 华南农业大学 | 2022-03-25 | — | — | CN | disclosed |
| CN-112939873-B | Trimethoprim hapten TMPH, artificial antigen, antibody and preparation method and application thereof | 华南农业大学 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260101051-A1 | SYSTEM AND METHOD FOR INTRA PREDICTION USING FRACTIONAL-PEL BLOCK VECTOR | FIP1L1, ETV1, FAP | ACHE 2679/4885CHRM1 4298/4885CHRM3 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.